Genmin【GEN】銘柄情報

Genmin Limited (GEN) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.008

( - )

買値

0.008

売値

0.009

出来高

0.00

0.00 日の範囲 0.00

0.005 52 週間の範囲 0.034

時価総額

27.676M

前日終値

0.008

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

AUD 4,790,391

発行済株式数

3,459,536,102

配当利回り

PER

-0.39

1 株当たり利益 (EPS)

-0.01

歳入

純利益

-14.15M

Genmin Limited, a mineral exploration and project development company, produces iron ore in Africa. Its flagship property comprises 100% owned project, the Baniaka iron ore located in south-east Gabon, west Central Africa. Genmin Limited was incorporated in 2010 and is based in West Perth, Australia... Genmin Limited, a mineral exploration and project development company, produces iron ore in Africa. Its flagship property comprises 100% owned project, the Baniaka iron ore located in south-east Gabon, west Central Africa. Genmin Limited was incorporated in 2010 and is based in West Perth, Australia. 詳細を表示

セクター

Materials

業界

Mining

ウェブサイト

www.genmingroup.com

本社

West Perth, Australia

設立

2026

Genmin Limited is listed in the Materials sector of the オーストラリア証券取引所 with ticker GEN. The last closing price for Genmin was AUD0.01. Over the last year, Genmin shares have traded in a share price range of AUD 0.005 to AUD 0.034.

Genmin currently has 3,459,536,102 shares in issue. The market capitalisation of Genmin is AUD27.68 million. Genmin has a price to earnings ratio (PE ratio) of -0.39.

Genmab Files IND for HuMax-TF-ADC

Company Announcement IND for HuMax(R)-TF-ADC submitted to FDA Genmab's first IND submission for antibody-drug conjugate (ADC) product...

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case COPENHAGEN, Denmark, July 15, 2013...

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Company Announcement First Phase III study with subcutaneous formulation of ofatumumab Ofatumumab to be investigated in new autoimmune...

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Media Release Antibody-drug conjugate (ADC) to be developed for cancer Combines strength of HuMax(R)-TAC with next generation...

Teprotumumab Restarts Clinical Development in New Indication

Company Announcement Teprotumumab (RG1507) to be investigated for new indication River Vision Development Corporation to conduct...

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

Company Announcement Genmab establishes Sponsored Level 1 ADR program Genmab ADRs can be traded on US over-the-counter (OTC) market...

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Company Announcement Median 22.4 month progression free survival in patients treated with ofatumumab plus chlorambucil, an improvement of...

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec have filed for re-hearing in the United States COPENHAGEN, Denmark, May 17, 2013 (GLOBE...

Genmab Announces Financial Results for the First Quarter of 2013

COPENHAGEN, Denmark, May 7, 2013 (GLOBE NEWSWIRE) -- Interim Report First Quarter 2013 Arzerra(r) received approval in Japan Arzerra net...

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

Company Announcement 95% overall response rate and 43% complete response rate in patients with previously untreated chronic lymphocytic...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.008	0.0085	0.008	2145042	0.00800466	DE
4	0	0	0.008	0.009	0.007	4518838	0.0080858	DE
12	0.001	14.2857142857	0.007	0.009	0.005	4694795	0.00733566	DE
26	-0.001	-11.1111111111	0.009	0.01	0.005	6738376	0.00786789	DE
52	-0.017	-68	0.025	0.034	0.005	4517847	0.00921459	DE
156	-0.157	-95.1515151515	0.165	0.2	0.005	2317161	0.01867215	DE
260	-0.252	-96.9230769231	0.26	0.28	0.005	1401665	0.02947521	DE